Purpose An intravenous (IV) erlotinib formulation has not been characterized in cancer
patients but may be useful in those with gastrointestinal abnormalities that impact on the …

Purpose The objectives of this phase I dose-finding study of erlotinib were to investigate the
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …

Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …

Purpose: To assess the feasibility of administering erlotinib, an inhibitor of epidermal growth
factor receptor (EGFR) tyrosine kinase, in combination with paclitaxel and carboplatin, and …

Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …

Erlotinib is currently marketed at fixed standard dosage against pancreatic cancer and non–
small-cell lung carcinoma. However, erlotinib pharmacokinetics (PK) is characterized by …

Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient
population with solid tumors, identify covariates, and explore relationships between …

Abstract Purpose: Erlotinib (Tarceva) is a potent epidermal growth factor receptor (HER1)
inhibitor. Infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) is a standard …

Purpose We investigated dose and pharmacokinetics of erlotinib in patients with hepatic
dysfunction or renal dysfunction. Patients and Methods Patients were assigned to one of …

The aim of this study was to evaluate the effect of coadministration of acid-reducing agents
on the pharmacokinetic exposure of orally administered epidermal growth factor receptor …